Overview

MD® Intimate Restore is a hormone-free, peptide-powered intimate rejuvenation serum developed by board-certified gynecologist Dr. Susan Lin, M.D., founder of La Canada Ventures, Inc. The formula combines stem cell–conditioned factors with collagen-boosting peptides to address vulvovaginal skin changes associated with aging, perimenopause, menopause, and postpartum recovery — without estrogen or other hormones.

This page summarizes the independent dermatological safety study (Medcin Instituto da Pele, Brazil, 2017) and the consumer-acceptance group study (GVI, Mexico) commissioned by the sponsor, La Canada Ventures, Inc.

Study #1: Dermatological Safety — Medcin Instituto da Pele (Brazil, 2017)

Study Population

55 participants screened and included, age 18–70 years (avg. 53.5 years), Fitzpatrick skin types I–IV. 54 completed the full protocol (one withdrawal for non-study reasons). Population was predominantly female (52 of 55).

Methodology

Three-phase patch-test compatibility study conducted in maximized conditions per ICDRG (International Contact Dermatitis Research Group) protocol:

• Phase 1 — Primary Dermal Irritation: Semi-occlusive patches applied to the back of each participant; 48-hour evaluation, with re-evaluation at 96 hours.
• Phase 2 — Cumulative Dermal Irritation: Eight repeated applications over three weeks with patch evaluation at each visit.
• Phase 3 — Dermal Sensitization: Re-challenge phase following completion of cumulative irritation to detect delayed allergic response.

Dermatological assessment performed at baseline and at the end of each phase by the Principal Investigator.

Results

Conclusion (verbatim from Principal Investigator)

Study #2: Consumer-Acceptance Group Study — GVI (Mexico)

Target Populations

• Group 1 — Postpartum Vaginal Birth: 25–35 years old, sexually active, daily use
• Group 2 — Postpartum C-Section: 25–35 years old, sexually active, daily use
• Group 3 — Menopause: 45–55 years old, sexually active or not, daily use

Intended Product Benefits Assessed

• Moisturizes to reduce skin irritation
• Nourishes to improve skin elasticity and texture
• Enhances feminine erogenous sensitivity

Key Group 1 (Postpartum Vaginal Birth) Findings

• 4 of 5 participants would recommend the product for daily use
• 4 of 5 participants would recommend MD® Intimate Restore to a friend or relative “for sure,” with the fifth saying “possibly”
• Of those who had used another intimate-care product before, 2 rated MD® Intimate Restore as “better” than the alternative; 1 as “same”

Note: Group study findings are consumer-acceptance survey data and are not a substitute for randomized controlled trial results. Reported here for transparency.

Physician Authority Behind MD® Intimate Restore

Dr. Susan Lin, M.D. is the physician founder and CEO of La Canada Ventures, Inc., creator of the MD® family of beauty and wellness brands. She is board-certified in Obstetrics and Gynecology and in Anti-Aging Medicine, with 35+ years of clinical practice. She authored the chapter “Feminine Rejuvenation” (Part 3.8, pp. 549–560) in Harry’s Cosmeticology, 9th Edition (Chemical Publishing Co., ISBN 978-0-8206-0179-3) — covering vulvar skin rejuvenation using novel stem cell cytokine topicals, the same scientific approach underlying MD® Intimate Restore.

Manufacturing & Regulatory

• Manufactured in the USA in a GMP-compliant, FDA-registered facility
• Sponsor: La Canada Ventures, Inc. (San Mateo, California) — a physician-founded, NMSDC MBE–certified (BA1137), WBENC WBE–certified (1702688), veteran-owned, federally registered (SAM.gov UEI GHQRVKN8GEG7) small business
• Trademark: MD Intimate Restore is a trademark owned by La Canada Ventures, Inc.

Press Coverage — 2015 Launch Announcement

Related Clinical Evidence